On the other hand, CRY inhibitors, like KS15, have demonstrated effectiveness in breast cancer cells by disrupting CRY-mediated transcriptional repression, leading to cell cycle arrest, apoptosis, and increased sensitivity to chemotherapy [27,28]. This evidence concerns the gene CRYL1 and breast carcinoma.